Corbus Pharmaceuticals (CRBP) has released an update.
The ongoing Phase 1 clinical trial for SYS6002 (CRB-701) in patients with metastatic urothelial cancer and other nectin-4 positive solid tumors has shown it to be well-tolerated, with most adverse events being low-grade and reversible. No high-grade adverse events or dose discontinuations have been reported. Pharmacokinetic data indicates dose-proportional increases and low accumulation, with lower free MMAE concentrations compared to enfortumab vedotin. Early efficacy results are promising, with a 43% objective response rate and 71% disease control rate at doses predicted to be therapeutically relevant. The longest response has been 11 cycles and ongoing, particularly in nectin-4 positive mUC and cervical patients at higher doses.
For further insights into CRBP stock, check out TipRanks’ Stock Analysis page.
